Pharmacokinetics of a new anti-HIV agent VP-0501 and development of its amino acid prodrug for improving oral bioavailability

Anti-HIV agent VP-0501의 생체이용성 향상을 위한 아미노산 프로드럭 개발 및 약물동태연구

  • Cho, Hee-Jeong (College of Veterinary Medicine, Konkuk University) ;
  • Choi, Kyung-Ae (College of Veterinary Medicine, Konkuk University) ;
  • Sung, Ji-Min (College of Veterinary Medicine, Konkuk University) ;
  • Jeong, Sang-Min (College of Veterinary Medicine, Konkuk University) ;
  • Han, Jin-Soo (College of Veterinary Medicine, Konkuk University) ;
  • Kim, Jin-Suk (College of Veterinary Medicine, Konkuk University) ;
  • Shin, Ho-Chul (College of Veterinary Medicine, Konkuk University)
  • Accepted : 2006.01.15
  • Published : 2006.03.29


We have studied pharmacokinetics of a new anti-human immunodeficiency virus (HIV) agent VP-0501 and its amino acid prodrug VP-0501AL which is designed to improve oral bioavailability. After oral administration at 100 mg/kg dose in rats (n = 4), VP-0501 was not detectable in plasma (<50 ng/ml), while after the administration of VP-0501AL, VP-0501 was quantitatively detected, at least for 8 hrs, with Cmax of ca. $2.5{\mu}g/ml$ and AUC of $8hr^{\ast}{\mu}g/ml$. When VP-0501 was intravenously administered at 50mg/kg, this compound appeared at a marginal level in plasma with AUC of $2hr^{\ast}{\mu}g/ml$, $t_{1/2}$ of 2 hr, $C_0$ of $0.7{\mu}g/ml$, and MRT of 3 hr. On the other hand, with intravenous VP-0501AL at the same dose, both the prodrug VP-0501AL and its metabolite VP-0501 appeared comparatively at higher level in the plasma: pharmacokinetic parameters of VP-0501AL including $Vd_{\beta}$, AUC, $t_{1/2,{\beta}}$, $C_0$, $CL_{tot}$, and MRT were ca. 2 L/kg, $70hr^{\ast}{\mu}g/ml$, 2 hr, $180{\mu}g/ml$, 0.7 L/hr/kg, and 1 hr, respectively. These results demonstrate that attachment of amino acid alanine to VP-0501 is an effective approach for improvement of its oral bioavailability. Therefore, VP-0501AL is expected to become a new highly bioavailable and potent anti-AIDS drug candidate/lead compound.


  1. Acosta EP, Fletcher CV. Valacyclovir. Ann Pharmacother 1997, 31, 185-191
  2. Arnold E, Das K, Ding J, Yadav PN, Hsiou Y, Boyer PL, Hughes SH. Targeting HIV reverse transcriptase for anti-AIDS drug design: structural and biological considerations for chemotherapeutic strategies. Drug Des Discov 1996, 13, 29-47
  3. Bardsley-Elliot A, Perry CM. Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection. Paediatr Drugs 2000, 2, 373-407
  4. Beutner KR. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Res 1995, 28, 281-290
  5. Bras AP, Sitar DS, Aoki FY. Comparative bioavailability of acyclovir from oral valacyclovir and acyclovir in patients treated for recurrent genital herpes simplex virus infection. Can J Clin Pharmacol 2001, 8, 207-211
  6. Dannenfelser RM, He H, Joshi Y, Bateman S, Serajuddin AT. Development of clinical dosage forms for a poorly water soluble drug I: Application of polyethylene glycol-polysorbate 80 solid dispersion carrier system. J Pharm Sci 2004, 93, 1165-1175
  7. De Clercq E, Field HJ. Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol 2006, 147, 1-11
  8. Haase AT. Viral gene expression and pathogenesis in three emerging diseases: HIV and AIDS; HTLV-I and HAM/TSP; and HHV-8 and Kaposi's sarcoma. FEMS Immunol Med Microbiol 1997, 18, 301-305
  9. Kondo N, Iwao T, Hirai K, Fukuda M, Yamanouchi K, Yokoyama K, Miyaji M, Ishihara Y, Kon K, Ogawa Y, et. al. Improved oral absorption of enteric coprecipitates of a poorly soluble drug. J Pharm Sci 1994, 83, 566-570
  10. Lin JH, Storey DE, Chen IW, Xu X. Improved oral absorption of L-365,260, a poorly soluble drug. Biopharm Drug Dispos 1996, 17, 1-15<1::AID-BDD934>3.0.CO;2-G
  11. Lorenzi PL, Landowski CP, Song X, Borysko KZ, Breitenbach JM, Kim JS, Hilfinger JM, Townsend LB, Drach JC, Amidon GL. Amino Acid Ester Prodrugs of 2-Bromo-5,6-dichloro-1-$\beta$-D-ribofuranosyl) benzimidazole Enhance Metabolic Stability in Vitro and in Vivo. J Pharmacol Exp Ther 2005, 314, 883-890
  12. Song X, Vig BS, Lorenzi PL, Drach JC, Townsend LB, Amidon GL. Amino acid ester prodrugs of the antiviral agent 2-bromo-5,6-dichloro-1-($\beta$-D-ribofuranosyl) benzimidazole as potential substrates of hPEPT1 transporter. J Med Chem 2005, 48, 1274-1277
  13. Sridevi S, Chauhan AS, Chalasani KB, Jain AK, Diwan PV. Enhancement of dissolution and oral, bioavailability of gliquidone with hydroxy propyl-betacyclodextrin. Pharmazie 2003, 58, 807-810
  14. Sriram D, Yogeeswari P, Srichakravarthy N, Bal TR. Synthesis of stavudine amino acid ester prodrugs with broad-spectrum chemotherapeutic properties for the effective treatment of HIV/AIDS. Bioorg Med Chem Lett 2004, 14, 1085-1087
  15. Subramanian N, Ray S, Ghosal SK, Bhadra R, Moulik SP. Formulation design of self-microemulsifying drug delivery systems for improved oral bioavailability of celecoxib. Biol Pharm Bull 2004, 27, 1993-1999
  16. Tantillo C, Ding J, Jacobo-Molina A, Nanni RG, Boyer PL, Hughes SH, Pauwels R, Andries K, Janssen PA, Arnold E. Locations of anti-AIDS drug binding sites and resistance mutations in the threedimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol 1994, 243, 369-387
  17. Tashiro K, Ikegawa M, Yabe D, Honjo T. [Anti-HIV-1 genes; genetic restriction of AIDS pathogenesis by gene variants]. Nippon Rinsho 1999, 57, 967-974
  18. Vig BS, Lorenzi PJ, Mittal S, Landowski CP, Shin HC, Mosberg HI, Hilfinger JM, Amidon GL. Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis. Pharm Res 2003, 20, 1381-1388
  19. Young SD, Britcher SF, Tran LO, Payne LS, Lumma WC, Lyle TA, Huff JR, Anderson PS, Olsen DB, Carroll SS, et. al. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1995, 39, 2602-2605